Biocon Ltd
NSE:BIOCON
Operating Margin
Biocon Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Biocon Ltd
NSE:BIOCON
|
479.4B INR |
10%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.1B USD |
31%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
159.5B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
147B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
100.7B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
130.9B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.8B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
58.8B USD |
-7%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Biocon Ltd
Glance View
In the bustling world of biotechnology, Biocon Ltd. stands as a beacon of innovation, rooted in its Indian origins yet extending its influence globally. Founded in 1978 by Kiran Mazumdar-Shaw, a visionary with a degree in fermentation science, Biocon began its journey as a maker of enzymes before transforming into a formidable force in biopharmaceuticals. This transformation was driven by the company's emphasis on research and development, leading to groundbreaking advancements in biosimilars, generics, and novel biotherapeutics. These products cater to critical areas such as oncology, diabetes, and autoimmune diseases. The company's success hinges on its ability to blend scientific rigor with entrepreneurial flair, enabling it to deliver high-quality, cost-effective solutions in a market traditionally dominated by Western giants. Biocon's revenue model is intricately woven from various strands of its expansive portfolio. A significant chunk emerges from its biologics division, where it manufactures biosimilars that serve as cost-friendly alternatives to expensive biologic drugs. Simultaneously, the company capitalizes on its expertise in small molecule APIs and branded formulations, which are integral to its generics business. Furthermore, collaborations and partnerships with global pharmaceutical companies amplify its reach, facilitating market access and regulatory navigation. Through these strategic undertakings, Biocon not only bolsters its financial performance but also reinforces its commitment to enhancing healthcare affordability and accessibility across the globe.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Biocon Ltd's most recent financial statements, the company has Operating Margin of 9.7%.
You don't have any saved screeners yet